Viking Therapeutics Rises 2.88% as Shares Remain Down for Month
The shares gained in the latest session, while Zacks consensus estimates point to a projected quarterly loss and no annual revenue.
Makkler Newsroom · Oct 10, 01:20 AM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $97.00 (+261.9%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.